# Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections

> **NIH NIH U19** · UNIVERSITY OF TEXAS MED BR GALVESTON · 2022 · $7,043,167

## Abstract

OVERALL - Project Summary/Abstract
Among viruses that cause disease in humans the filoviruses, Ebolavirus and Marburgvirus, stand out for their
impressive lethality. These viruses are the most deadly human pathogens known to man with reported case
fatality rates of up to 90%. The recent unprecedented 2013-16 epidemic of Zaire ebolavirus in West Africa
resulting in over 28,000 cases and 11,000 deaths demonstrates the ability of filoviruses to emerge in new
regions. In addition to natural outbreaks, Ebolavirus and Marburgvirus are known to have been the subjects of
former biological weapons programs and have the potential for deliberate misuse. Currently, there are no filovirus
vaccines or treatments approved for human use. For these reasons Ebolavirus and Marburgvirus have recently
been included as only two of eleven human pathogens on the new US Department of Health and Human Services
(HHS) Tier 1 list of Category A select agents. All three Research Projects (RP) that comprise the Center focus
on developing broad spectrum rapid acting vaccines or therapeutics against all medically relevant variants and
species of the family Filoviridae. RP1 employs recombinant vesicular stomatitis virus (VSV)-based rapid acting
vaccines, RP2 focuses on fully human anti-filovirus monoclonal antibodies, and RP3 focuses on anti-filovirus
small interfering RNAs, small molecule antivirals (GS-5734 and favipiravir), and combination treatments. A
unique aspect of this Center is that these approaches represent a very small cohort of medical countermeasures
that have shown the ability to provide complete single injection vaccination or therapeutic protection of nonhuman
primates against filoviruses. This level of readiness is a major strength and consequential advantage of our
Center. The primary objective of the Advancement of Vaccines and Treatments for Filovirus Infections Center is
to perform “well documented” and also “pivotal” NHP studies that will facilitate the development of products used
for the broad spectrum treatment of filovirus infections. The synergy and cooperation among the three RPs, the
Administrative Core, and the Biosafety Level (BSL)-4 Core is built into the Center by design as all three RPs
work together to assess and combine countermeasures for enhanced efficacy. Quality system data management
will be employed in both the preparation of advanced stage test articles and in the conduct of animal studies.

## Key facts

- **NIH application ID:** 10356834
- **Project number:** 5U19AI142785-04
- **Recipient organization:** UNIVERSITY OF TEXAS MED BR GALVESTON
- **Principal Investigator:** Thomas William Geisbert
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $7,043,167
- **Award type:** 5
- **Project period:** 2019-03-08 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10356834

## Citation

> US National Institutes of Health, RePORTER application 10356834, Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections (5U19AI142785-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10356834. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*